| Vol. 13.21 – 10 June, 2021 |
| |
|
|
| Scientists reported that the activation of polymorphonuclear myeloid-derived suppressor cells during pregnancy was closely associated with fetal growth. [Cellular & Molecular Immunology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators constructed PRL-1 overexpressed human placental MSCs in an attempt to enhance the suppressive function of adipogenesis in Graves’ ophthalmopathy animal models. [Stem Cell Research & Therapy] |
|
|
|
| Two separate dextran sulfate sodium and 2,4,6-trinitrobenzenesulfonic acid induced inflammatory bowel disease mouse models were intraperitoneally administered MSCs-Exo extracted from human umbilical cord MSC culture supernatant. [Stem Cell Research & Therapy] |
|
|
|
| Researchers investigated the expression and distribution of the main components of the serotoninergic system in human amniotic tissue and in human amniotic epithelial cells in vitro, as an alternative model of early human embryo development. [Biology of Reproduction] |
|
|
|
| Human umbilical cord blood-MSCs were infected with the adenovirus expressing GFP-VEFG fusion protein to overexpress VEGF165 or the adenovirus expressing GFP as control. [Journal of Gene Medicine] |
|
|
|
| In this three-month follow-up study, investigators examined discharged patients who had received human umbilical cord-MSC therapy to assess the safety of this therapy and the health-related quality of life of these patients. [Stem Cells and Development] |
|
|
|
|
| The authors focus on the latest research and applications of human-derived umbilical cord MSC in the treatment and management of T2DM, exploring and systematizing the key effects of both umbilical cord MSC and its factor-rich secretome accordingly with the major complications associated to T2DM. [Cell and Tissue Research] |
|
|
|
|
| Calidi Biotherapeutics, Inc. announced its partnership with GenScript ProBio for assistance in the advertisement and distribution of Calidi’s proprietary technology platform: SuperNova-1 (SNV-1). The SNV-1 platform is composed of allogeneic, adipose-derived-MSC loaded with an oncolytic agent such as the vaccinia virus. [Calidi Biotherapeutics, Inc.] |
|
|
|
|
| September 6 – 10, 2021 Virtual |
|
|
|
|
|
| University of Pisa – Pisa, Italy |
|
|
|
| UT Southwestern Medical Center – Dallas, Texas, United Statess |
|
|
|
| Memorial Sloan Kettering Cancer Center – New York, New York, United States |
|
|
|
| University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| Columbia University Medical Center – New York, New York, United States |
|
|
|
|